行情

CBLI

CBLI

克利夫兰生物实验室
NASDAQ

实时行情|Nasdaq Last Sale

2.980
+0.010
+0.34%
盘后: 3.050 +0.07 +2.35% 18:54 12/04 EST
开盘
2.950
昨收
2.970
最高
3.090
最低
2.950
成交量
14.98万
成交额
--
52周最高
5.43
52周最低
0.5150
市值
3,878.88万
市盈率(TTM)
-14.7015
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
Cytocom, Inc. Issues Shareholder Letter To Stockholders Of Cytocom And BioLabs
  WINTER PARK, Fla., Oct. 21, 2020 /PRNewswire/ -- Cytocom, Inc., a leading biopharmaceutical company in the area of immune-modulation, today announced that its Chief Executive Officer, Michael K. Handley, has
Benzinga · 10/21 12:32
The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20)
Benzinga · 10/21 12:04
Mid-Afternoon Market Update: Dow Rises 1%; Aptinyx Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded up 1% to 28,476.42 while the NASDAQ rose 1.06% to 11,600.59. The S&P also rose, gaining 1.15% to 3,466.20.
Benzinga · 10/20 18:34
Mid-Day Market Update: Cleveland BioLabs Jumps On Merger News; Isoray Shares Slide
Midway through trading Tuesday, the Dow traded up 0.42% to 28313.84 while the NASDAQ rose 0.26% to 11508.37. The S&P also rose, gaining 0.45% to 3442.37.
Benzinga · 10/20 16:12
Why Cleveland BioLabs Stock Is Trading Higher Today
Cleveland BioLabs (NASDAQ: CBLI) shares are trading higher on Tuesday after the company, along with Cytocom, announced they have entered into a definitive merger agreement to combine their businesses in an all-stock transaction.
Benzinga · 10/20 15:08
Mid-Morning Market Update: Markets Open Higher; Procter & Gamble Beats Q1 Views
Following the market opening Tuesday, the Dow traded up 0.82% to 28425.94 while the NASDAQ rose 0.84% to 11575.60. The S&P also rose, gaining 0.90% to 3,457.87.
Benzinga · 10/20 14:16
美股盘前消息速报
新浪财经 · 10/20 12:41
美股盘前消息速报
新浪财经 · 10/20 12:41
更多
财务预测
每股收益每股净资产每股现金流
实际值(美元)
预测值(美元)
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解CBLI最新的财务预测,通过CBLI每股收益,每股净资产,每股现金流等数据分析克利夫兰生物实验室近期的经营情况,然后做出明智的投资选择。
EPS
机构持股
总机构数: 25
机构持股: 34.57万
持股比例: 2.66%
总股本: 1,301.64万
类型机构数股数
增持
1
6,047
建仓
5
3.27万
减持
6
10.91万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+2.89%
制药与医学研究
+1.72%
高管信息
Chairman/Independent Director
Lea Verny
President
Langdon Miller
Chief Executive Officer/Chief Financial Officer/Vice President - Finance
Christopher Zosh
Chief Scientific Officer
Andrei Gudkov
Independent Director
Alexander Andryushechkin
Independent Director
Anna Evdokimova
Independent Director
Ivan Fedyunin
Independent Director
Randy Saluck
Independent Director
Daniil Talyanskiy
  • 分红
  • 拆股
  • 内部人交易
暂无数据
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取
CBLI 简况
Cleveland BioLabs, Inc.(CBLI)是一家生物制药公司。该公司正在开发激活免疫系统的方法,以解决严重的医疗需求。该公司的Toll样免疫受体激活剂平台用于减轻放射损伤并应用于免疫肿瘤学。该公司的先导候选产品是一种免疫刺激剂Entolimod,该公司正在开发Entolimod作为辐射对策以及肿瘤学与其他适应症的免疫疗法。该公司的其他产品包括CBLB612、Mobilan和CBL0137。CBLB612是一种天然免疫系统中另一种组织特异性成分的天然活化剂,另一种组织特异性成分为toll样受体2(TLR2)/toll样受体6(TLR6)异二聚体受体。Mobilan是一种指导TLR5及其激动配体表达的重组非复制型腺病毒。CBL0137是一种具有多靶向作用机制的小分子,可治疗多种癌症。
展开
热门股票
代码
价格
涨跌幅

微牛提供Cleveland BioLabs, Inc.(NASDAQ-CBLI)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CBLI股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CBLI股票基本功能。